Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEP1B | Q16820 | 3/20 | 0.78 |
| ▸ | BMP1 | P13497 | 5/20 | 0.74 |
| ▸ | MMP3 | P08254 | 4/20 | 0.71 |
| ▸ | MMP2 | P08253 | 4/20 | 0.69 |
| ▸ | MMP9 | P14780 | 4/20 | 0.69 |
| ▸ | CA2 | P00918 | 3/20 | 0.69 |
| ▸ | CA9 | Q16790 | 2/20 | 0.69 |
| ▸ | MMP13 | P45452 | 4/20 | 0.66 |
| ▸ | ADAM10 | O14672 | 1/20 | 0.66 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.66 |
| ▸ | MEP1A | Q16819 | 1/20 | 0.66 |
| ▸ | MMP1 | P03956 | 4/20 | 0.65 |
| ▸ | MMP8 | P22894 | 4/20 | 0.65 |
| ▸ | MMP7 | P09237 | 2/20 | 0.65 |
| ▸ | MMP12 | P39900 | 2/20 | 0.65 |
| ▸ | CA1 | P00915 | 1/20 | 0.60 |
| ▸ | MMP14 | P50281 | 1/20 | 0.60 |
| ▸ | MMP16 | P51512 | 1/20 | 0.60 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.58 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7348906 | 0.94 | MEP1B (0.86) | MEP1BBMP1MMP3MMP2MMP9 | |
| SCHEMBL6411677 | 0.89 | MEP1B (0.79) | MEP1BBMP1MMP3MMP2MMP9 | |
| SCHEMBL7003670 | 0.89 | BMP1 (0.72) | MEP1BBMP1MMP2MMP9CA2 | |
| SCHEMBL6421526 | 0.88 | BMP1 (0.78) | MEP1BBMP1MMP3MMP2MMP9 | |
| SCHEMBL7338644 | 0.88 | MEP1B (0.81) | MEP1BBMP1MMP3MMP2MMP9 | |
| SCHEMBL26772450 | 0.87 | MEP1B (1.00) | MEP1BBMP1MMP3MMP2MMP9 | |
| SCHEMBL8002039 | 0.87 | DAGLA (0.76) | MEP1BBMP1DAGLATAS2R14 | |
| SCHEMBL2513323 | 0.87 | MEP1B (0.72) | MEP1BBMP1MMP3MMP2MMP9 | |
| SCHEMBL7350511 | 0.86 | MEP1B (0.78) | MEP1BBMP1MMP3MMP2MMP9 | |
| SCHEMBL13898740 | 0.86 | MEP1B (0.74) | MEP1BBMP1MMP3MMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357139-A1 | SMALL MOLECULE INHIBITORS OF BACTERIAL TOXINS | Artizan Biosciences, Inc. | 2023-11-09 | — | — | US | disclosed |
| EP-1434993-B1 | METHODS OF ASSAYING CONNECTIVE TISSUE GROWTH FACTOR | FIBROGEN INC (US) | 2013-04-24 | — | — | EP | disclosed |
| US-20070020692-A1 | Methods of assaying connective tissue growth factor | FIBROGEN, INC. (US) | 2007-01-25 | — | — | US | disclosed |
| US-20050020607-A1 | Statin-MMP inhibitor combinations | NEWTON ROGER SCHOFIELD (US) | 2005-01-27 | — | — | US | disclosed |
| EP-1366765-A1 | Use of matrix metalloproteinase inhibitors for treating neurological disorders and promoting wound healing | WARNER-LAMBERT COMPANY LLC (US) | 2003-12-03 | — | — | EP | disclosed |
| US-20030113816-A1 | Methods of assaying connective tissue growth factor | FIBROGEN, INC. | 2003-06-19 | — | — | US | disclosed |
| US-20020049237-A1 | Statin-MMP inhibitor combinations | NEWTON ROGER SCHOFIELD (US) | 2002-04-25 | — | — | US | disclosed |
| US-6340709-B1 | ADMINISTERING BIPHENYLSULFONAMIDE DERIVATIVE | WARNER-LAMBERT COMPANY | 2002-01-22 | — | — | US | disclosed |
| EP-1098662-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2001-05-16 | — | — | EP | disclosed |
| EP-1063991-A1 | STATIN-MATRIX METALLOPROTEINASE INHIBITOR COMBINATIONS | WARNER-LAMBERT COMPANY LLC (US) | 2001-01-03 | — | — | EP | disclosed |
| WO-1998026773-A1 | USE OF MATRIX METALLOPROTEINASE INHIBITORS FOR TREATING NEUROLOGICAL DISORDERS AND PROMOTING WOUND HEALING | WARNER-LAMBERT COMPANY (US) | 1998-06-25 | — | — | WO | disclosed |
| EP-0845987-A1 | C-PROTEINASE INHIBITORS FOR THE TREATMENT OF DISORDERS RELATED TO THE OVERPRODUCTION OF COLLAGEN | FIBROGEN, INC. (US) | 1998-06-10 | — | — | EP | disclosed |
| EP-0606046-B1 | Arylsulfonamido-substituted hydroxamic acids | CIBA GEIGY AG (CH) | 1997-10-08 | — | — | EP | disclosed |
| US-5646167-A | ADMINISTERED AS METALLOPROTEINASE INHIBITOR, ANTITUMOR OR ANTICARCINOGENIC AGENT | CIBA-GEIGY CORPORATION (US) | 1997-07-08 | — | — | US | disclosed |
| WO-1997005865-A1 | C-PROTEINASE INHIBITORS FOR THE TREATMENT OF DISORDERS RELATED TO THE OVERPRODUCTION OF COLLAGEN | FIBROGEN, INC. (US) | 1997-02-20 | — | — | WO | disclosed |
| WO-1996040101-A1 | CERTAIN ARYLSULFONAMIDO-SUBSTITUTED HYDROXAMIC ACIDS FOR THE TREATMENT OF CERTAIN TUMORS | NOVARTIS AG (CH) | 1996-12-19 | — | — | WO | disclosed |
| US-5552419-A | METALLOPROTEINASE INHIBITORS | CIBA-GEIGY CORPORATION (US) | 1996-09-03 | — | — | US | disclosed |
| US-5506242-A | METALLOELASTASE INHIBITOR; TREATS EMPHYSEMA | CIBA-GEIGY CORPORATION (US) | 1996-04-09 | — | — | US | disclosed |
| US-5455258-A | Useful as inhibitors of matrix-degrading metalloproteinase enzymes such as stromelysin and/or collegenase | CIBA-GEIGY CORPORATION (US) | 1995-10-03 | — | — | US | disclosed |
| EP-0606046-A1 | Arylsulfonamido-substituted hydroxamic acids | CIBA-GEIGY AG (CH) | 1994-07-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357139-A1 | SMALL MOLECULE INHIBITORS OF BACTERIAL TOXINS | FABP2, APC, SI | MEP1B 3750/4885BMP1 3685/4885MMP3 454/4885 |
| US-20050020607-A1 | Statin-MMP inhibitor combinations | MMP9, TIMP3, MMP3 | MEP1B 2040/4885BMP1 922/4885MMP3 3/4885 |
| US-20020049237-A1 | Statin-MMP inhibitor combinations | MMP9, TIMP3, MMP3 | MEP1B 2040/4885BMP1 922/4885MMP3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.